25052450
2014 Aug
Sarcopenia caused by hyperthyroidism from thyroid-stimulating hormone-suppressive therapy is one possible explanation for sorafenib dose-limiting toxicity in patients with differentiated thyroid cancer (DTC). Another possible explanation is that DTC patients in the considered trial were treated approximately twice as long as the renal-cell and hepatocellular carcinoma patients.

